Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: liver

Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  November 9, 2017

Medications for serious or life-threatening conditions may receive accelerated approval from the U.S. Food and Drug Administration (FDA) by showing an effect on surrogate measures that are reasonably likely to predict a treatment’s clinical benefit. Post-approval confirmatory drug trials are then required to determine whether or not these effects translate into clinical improvements. In recent…

Filed under:Axial SpondyloarthritisConditionsDrug UpdatesResearch Rheum Tagged with:accelerated approvalAnkylosing SpondylitisClinicaldrugefficacyFDAMedicationoutcomePsoriasisPsoriatic ArthritisResearchrheumatologySafetysecukinumabstudyTreatmenttrial

AndreyCherkasov / Shutterstock.com

Rheumatic Disease Does Not Preclude Pregnancy

Ruth Jessen Hickman, MD  |  November 9, 2017

Preconception planning is essential to help women with autoimmune disease have optimal pregnancy outcomes. Unplanned pregnancy can also negatively impact disease course in some patients. Yet many rheumatologic patients of childbearing age do not receive adequate contraception or prepregnancy education and counseling. Rheumatologists must work collaboratively with other healthcare providers to make sure rheumatic patients…

Filed under:Conditions Tagged with:Autoimmune diseasecontraceptivecounselingEducationInflammatory MyopathiesLupusoutcomepatient carepregnancyRheumatic DiseaseRheumatoid arthritisrheumatologistriskSystemic sclerosisVasculitisWomen

Rheumatology Health Professionals’ Awards, Appointments and Announcements November 2017

Carol Patton  |  November 8, 2017

Dr. Sherine Gabriel Joins Board of Trustees In July, ACR Past President Sherine E. Gabriel, MD, MSc, joined the New York Academy of Medicine Board of Trustees. Dr. Gabriel is a distinguished professor and dean of Rutgers Robert Wood Johnson Medical School. As dean emerita of Mayo Medical School, Dr. Gabriel developed successful clinical research training and career development…

Filed under:Career DevelopmentProfessional TopicsResearch Rheum Tagged with:AwardsCareerProfilepromotionResearchrheumatologistrheumatology health professionals

Researchers Examine Lifetime Risk of Total Hip Replacements

Arthritis Care & Research  |  November 6, 2017

Total hip replacement (THR) surgery is an effective way to reduce pain and improve function in people with advanced hip osteoarthritis (OA). In light of aging populations, there’s a need to use contemporary, population-level data to plan for future service provision. In a study designed to compare THR data across countries, researchers demonstrated a significant increase in the overall use of and lifetime risk for THR from 2003 to 2013. Women consistently had a higher lifetime risk of surgery than men in all five countries studied, whereas men in all five countries demonstrated a significant increase in lifetime risk for THR over time…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis Care & Researchhiphip arthroplastyosteoarthritis (OA)surgerytotal hip replacement

Year in Review: The ACR Advances Education, Rheumatic Disease Awareness, Strategic Planning in 2017

Sharad Lakhanpal, MBBS, MD  |  November 5, 2017

It seems like yesterday I was asked to write my first presidential column, and here I am penning my last. It’s incredible how fast the time goes and yet how much gets done. That progress is made possible by the dedicated and talented group of ACR volunteers and staff. This year, the College has had…

Filed under:Patient PerspectiveResearch RheumWorkforce Tagged with:AC&RAffordable Care Act (ACA)American College of Rheumatology (ACR)AwarenessCDCCommittee on Rheumatologic Care (CORC)DatabasedrugEducationFDAgoalmissionResearchRheumatic DiseaserheumatologistRISETraining

Unwise Choices: EHRs, PBMs, Drug Costs Are Leading to Physician Burnout

Simon M. Helfgott, MD  |  November 5, 2017

My dear electronic health records How do I dislike thee? Let me count the ways Adaptation of Sonnet 43 By Elizabeth Barrett Browning, 1806–1861 As my tenure as physician editor winds down, it’s worth reviewing some of the more nettlesome issues confronting clinicians that have been previously discussed in these pages and gauge their current…

Filed under:EMRsInsuranceOpinionPractice SupportRheuminationsSpeak Out RheumWorkforce Tagged with:burnoutCareercostsdrugEHRElectronic health recordsHealthcareinsurancepharmacy benefit managersphysicianPractice Managementrheumatologist

U.S. Scientists Unveil Powerful New Tools to Fix Genetic Faults

Julie Steenhuysen  |  October 26, 2017

CHICAGO (Reuters)—U.S. scientists on Wednesday unveiled two new molecular editing tools designed to fix mutations that cause the majority of human genetic diseases, some of which have no known treatment. One technique, by David Liu of Harvard University and the Broad Institute of MIT and Harvard, offers a highly precise way to fix single-letter mistakes…

Filed under:ConditionsTechnology Tagged with:base editingCRISPR-Cas9 gene editing toolDavid LiuFeng Zhangfix genetic mutations

U.S. to Promote Use of Opioid Alternatives to Treat Addiction

Toni Clarke  |  October 26, 2017

(Reuters)—The U.S. Food and Drug Administration plans to encourage opioid addicts to use less harmful opioid drugs such as methadone and buprenorphine, a radical shift in policy that could agitate those in the addiction field who believe abstinence is the only effective treatment. Speaking before the House Committee on Energy and Commerce on Wednesday, FDA…

Filed under:Drug Updates Tagged with:addiction treatmentbuprenorphineFDA Commissioner Scott Gottliebmethadonenational opioid addiction epidemicopioid alternativesopioid crisisopioid substituteU.S. Food and Drug Administration (FDA)

Some Middle-Class Americans Worry Trump Health Subsidies Cut Will Hurt

Tim Reid and Yasmeen Abutaleb  |  October 19, 2017

PHILADELPHIA (Reuters)—Tom Westerman voted for Donald Trump in last year’s election but says he might not do so again after the president cut off billions of dollars in Obamacare subsidies to health insurance companies. “It really upset me,” said Westerman, 63, a self-described “middle-class guy” with an annual household income of about $60,000 in the…

Filed under:Legislation & Advocacy Tagged with:health insurance costsmiddle-class AmericansObamacare subsidiesTrump health subsidies cut

ACR Works to Eliminate Part B Drug Costs from MIPS Payment Adjustments

Kelly Tyrrell  |  October 19, 2017

The ACR is taking steps to clarify a proposed rule from the Centers for Medicare and Medicaid Services (CMS) that, as currently written, would consider the cost of Part B drugs when calculating physician reimbursement under the Merit-Based Incentive Payment System (MIPS). “The ACR is concerned about this, because large cuts to reimbursement for pass-through…

Filed under:Billing/CodingLegislation & AdvocacyPractice Support Tagged with:CMS proposed ruleMACRAMIPSPart B drug costs

  • « Previous Page
  • 1
  • …
  • 60
  • 61
  • 62
  • 63
  • 64
  • …
  • 125
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences